Weisman Omri, Schonherz Yael, Harel Tal, Efron Martin, Elazar Maya, Gothelf Doron
The Child and Adolescent Psychiatry Divison, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
The Child and Adolescent Psychiatry Divison, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
Isr J Psychiatry. 2018;55(2):59-63.
Adherence to medication is a key factor for successful treatment of children with ADHD. However, most children do not adhere to their pharmacotherapy regimen, and have no contact with their physician during the first month of pharmacotherapy. A mobile health (mHealth) approach may bridge the gap between physicians and patients, allowing for more frequent communications as well as better monitoring of adherence to the prescribed treatment.
The study sample included 39 children with ADHD (27 boys), aged 9.56±2.41 years. Participants were randomly assigned to one of the following two groups: (1) a study group in which participants and their parents were prompted to use a mobile application (i.e., mobile app or app); or to (2) a control group in which participants were treated as usual, without the app. Pill counts, which is a common strategy for confirming medication adherence, was recorded at week 4 and week 8. Clinical assessment conducted at baseline, week 4, and week 8.
Participants who were prescribed with the app demonstrated higher overall pill counts over 8-weeks period, F=4.33, p<.05. In addition, a significant improvement in total CRS score was found among the study group compared to controls in week 4 and week 8, F=4.74, p<.05.
The current study provides initial support for the feasibility of a new mobile app in promoting adherence to stimulants among youth with ADHD.
坚持服药是成功治疗多动症儿童的关键因素。然而,大多数儿童不遵守药物治疗方案,并且在药物治疗的第一个月内未与医生联系。移动健康(mHealth)方法可能会弥合医生与患者之间的差距,实现更频繁的沟通以及更好地监测对规定治疗的依从性。
研究样本包括39名多动症儿童(27名男孩),年龄9.56±2.41岁。参与者被随机分配到以下两组之一:(1)研究组,参与者及其父母被提示使用移动应用程序(即移动应用或应用程序);或(2)对照组,参与者按常规治疗,不使用该应用程序。在第4周和第8周记录药丸计数,这是确认药物依从性的常用策略。在基线、第4周和第8周进行临床评估。
被规定使用该应用程序的参与者在8周期间的总体药丸计数更高,F = 4.33,p <.05。此外,在第4周和第8周,研究组的总CRS评分与对照组相比有显著改善,F = 4.74,p <.05。
本研究为一种新的移动应用程序在促进多动症青少年对兴奋剂的依从性方面的可行性提供了初步支持。